A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Diabetic neuropathies; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TODINELI
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Status changed from recruiting to completed.
- 20 Jan 2017 Results published in the Diabetologia.